Selegiline Transdermal System (STS): Assessments of Dermal Safety in Human

Volume: 23, Issue: 3, Pages: 179 - 187
Published: Jan 1, 2005
Abstract
The selegiline transdermal system (STS) is being developed to treat major depressive disorder. In a Phase I clinical study, the STS (20 mg/20 cm 2 ) produced mild dermal irritability and demonstrated a low potential for contact allergenicity. In Phase III multicenter studies in major depression, over 1800 patients have been evaluated for dermal safety to reveal an overall rate of application site reactions (ASRs) with STS of 21.8% compared with...
Paper Details
Title
Selegiline Transdermal System (STS): Assessments of Dermal Safety in Human
Published Date
Jan 1, 2005
Volume
23
Issue
3
Pages
179 - 187
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.